title: [The possibilities of using himantane in the treatment of Parkinson's disease].
abstract: The domestic drug himantane has been used as a monotherapy in dosage 25 mg daily during 12 weeks in patients with Parkinson's disease. Patient's state has been assessed using clinical, electromyographic, electroneuromyographic, EEG and psychometric (UPDRS and other scales) methods. The preparation used is well tolerated, induces the significant decrease of movement disorders, i.e. tremor, and exerts a positive effect on emotional and personality disturbances. The clinical changes have been confirmed by electroneuromyographic data and EEG.
authors.forename: E A
authors.initials: EA
authors.lastname: Katunina
authors.forename: A V
authors.initials: AV
authors.lastname: Petrukhova
authors.forename: G N
authors.initials: GN
authors.lastname: Avakian
authors.forename: E A
authors.initials: EA
authors.lastname: Val'dman
authors.forename: L N
authors.initials: LN
authors.lastname: Nerobkova
authors.forename: T A
authors.initials: TA
authors.lastname: Voronina
authors.forename: Kh S
authors.initials: KhS
authors.lastname: Saiadian
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*; D012720:Severity of Illness Index; D014202:Tremor / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000978:Antiparkinson Agents; C122112:N-(2-adamantyl)hexamethylenimine; D000218:Adamantane